Abstract 896P
Background
This study aimed to explore the efficacy and safety of pembrolizumab combined with chemotherapy as neoadjuvant therapy in patients with resectable locally advanced head and neck squamous cell carcinomas (LA-HNSCCs).
Methods
In this prospective, single-arm, single-centre clinical trial, patients meeting the inclusion criteria were treated neoadjuvant therapy of preoperatively with 200 mg pembrolizumab combined with 75 mg/m2 cisplatin and 175 mg/m2 paclitaxel. This was followed by surgery and postoperative adjuvant therapy. The primary endpoint was the postoperative pathological complete response (PCR) rate. All statistical analyses were performed using SPSS 26.
Results
A total of 22 patients were enrolled, and the baseline characteristics were shown in Fig. 1. The postoperative PCR rate, was 36.4% (8/22), and there was no delay to surgery due to adverse drug reactions. The rate of laryngeal function preservation was 90.9% (20/22). Delayed wound healing was the main surgical complication, with an incidence of 22.7% (5/22). The median follow-up time was 9.5 months, and only 1 patient (4.55%) suffered a regional recurrence.
Table: 896P
Variables | Number of patients | % |
Male/Female | 21/1 | |
Age (mean ± SD, years) | 58.1±10.49 (22∼69) | -- |
Primary site | ||
Oropharynx | 6 | 27.3 |
hypopharynx | 15 | 68.2 |
Oral Cavity | 1 | 4.5 |
Hypopharynx invasion (N=15) | ||
Fixed vocal cord | 9 | 60 |
Extend to esophagus | 2 | 13.3 |
Tobacco | ||
YES | 16 | 72.7 |
NO | 6 | 27.3 |
Alcohol | ||
YES | 15 | 68.2 |
NO | 7 | 31.8 |
P16 states | ||
Positive | 4 | 18.2 |
Negative | 18 | 81.8 |
T stage | ||
T1-T2 | 8 | 36.4 |
T3 | 7 | 31.8 |
T4 | 7 | 31.8 |
N stage | ||
N0-N1 | 3 | 13.6 |
N2 | 19 | 86.4 |
Stage | ||
II | 3 | 13.6 |
III | 3 | 13.6 |
IV | 16 | 72.7 |
PD-L1 combined positive score | ||
<5 | 7 | 31.8 |
5-10 | 2 | 9.1 |
≥10 | 13 | 59.1 |
Conclusions
Preoperative treatment with pembrolizumab and chemotherapy in resectable LA-HNSCC has a high PCR rate with no significant impact on surgical safety. This treatment was found to increase the rate of laryngeal function preservation. However, the effects of neoadjuvant immunotherapy on long-term prognosis in LA-HNSCCs require further study.
Clinical trial identification
Trial registration: Chinese Clinical Trial Registry, ChiCTR2200055719, Registered 16 January 2022.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Beijing Hope Run Special Fund of Cancer Foundation of China (Grant No.LC2021A16).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
889P - CT-based radiomics models to predict progression in locally advanced head and neck cancer treated with definitive chemoradiation
Presenter: Gema Bruixola
Session: Poster session 12
890P - Real-world survival outcomes and survival risk factors in elderly patients with locally advanced squamous cell carcinoma of the head and neck
Presenter: Nabil Saba
Session: Poster session 12
891P - Changing landscape of head and neck squamous cell carcinoma (HNSCC) treatment and survival in Thailand: A 13-year multicenter retrospective study of 6,319 patients
Presenter: Nuttapong Ngamphaiboon
Session: Poster session 12
892P - Real-world data validation of university of San Diego nomogram for the prediction of benefit of intensive treatment for locoregionally advanced head and neck cancer
Presenter: Javier Caballero Daroqui
Session: Poster session 12
893P - Tumor node stage shift following leukocyte interleukin injection neoadjuvant extends overall survival in treatment-naïve locally advanced oral cavity/soft palate squamous cell carcinoma
Presenter: Jozsef Timar
Session: Poster session 12
894P - Is pathological complete response (PCR) a surrogate endpoint of overall survival in patients with technically unresectable oral cavity cancers? A real-world data study of 900 plus patients
Presenter: Shatabdi Chakraborty
Session: Poster session 12
897P - Nanosomal docetaxel lipid suspension (NDLS) or docetaxel based neoadjuvant therapy in Head and neck squamous cell carcinoma: Post hoc analysis of a prospective, randomized study
Presenter: Darshit Shah
Session: Poster session 12
898P - Meta-analysis of two placebo-controlled trials of avasopasem manganese (AVA) in patients with locally advanced, head & neck cancer (LAHNC)
Presenter: Neal Dunlap
Session: Poster session 12
899P - Impact of COVID-19 pandemic on treatment and survival in head and neck squamous cell carcinoma (HNSCC) patients (IMPACCT Study)
Presenter: Berta Vilar Anglada
Session: Poster session 12